There’s a pressing need to align regulatory approval and market access processes, and the new EU HTA process introduces complexities and increased analytical requirements. By involving market access experts and Statisticians from the outset of trial design, we can increase the chances of successful reimbursement and access.

In this webinar, Marius Sieverding, Data Scientist, Veramed will share his insights on how best to collaborate in an evolving submission landscape from a Statistical and Clinical perspective. During the Q&A session, Marius will be joined by Arthur Allignol, Senior Principal Statistician, Daiichi Sankyo, a member of the PSI HTA special interest group, who will provide a unique perspective from the view of the sponsor.